Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various vet… Read more
Wuhan Hvsen Biotechnology Co Ltd (300871) - Total Liabilities
Latest total liabilities as of September 2025: CN¥839.94 Million CNY
Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has total liabilities worth CN¥839.94 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Wuhan Hvsen Biotechnology Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Wuhan Hvsen Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JiangSu Jin Tong Ling Fluid Mach
SHE:300091
|
China | CN¥3.70 Billion |
|
Nankang Rubber Tire Corp Ltd
TW:2101
|
Taiwan | NT$39.25 Billion |
|
Shutterstock
NYSE:SSTK
|
USA | $774.90 Million |
|
PT Semen Indonesia (Persero) Tbk
PINK:PSGTF
|
USA | $28.51 Trillion |
|
Besqab Pref B
ST:BESQAB-PREF-B
|
Sweden | Skr3.71 Billion |
|
Universal Stainless & Alloy
NASDAQ:USAP
|
USA | $118.25 Million |
|
Guangdong Skychem Technology Co. Ltd. A
SHG:688603
|
China | CN¥120.83 Million |
|
Ningbo Sunrise Elc Technology Co Ltd Class A
SHE:002937
|
China | CN¥938.74 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Wuhan Hvsen Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wuhan Hvsen Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wuhan Hvsen Biotechnology Co Ltd (2016–2024)
The table below shows the annual total liabilities of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.55 Billion | +5.68% |
| 2023-12-31 | CN¥1.47 Billion | +1.28% |
| 2022-12-31 | CN¥1.45 Billion | +28.93% |
| 2021-12-31 | CN¥1.12 Billion | +200.96% |
| 2020-12-31 | CN¥373.08 Million | +37.26% |
| 2019-12-31 | CN¥271.80 Million | +91.30% |
| 2018-12-31 | CN¥142.08 Million | +17.36% |
| 2017-12-31 | CN¥121.06 Million | +19.67% |
| 2016-12-31 | CN¥101.16 Million | -- |